...
【24h】

Intervertebral disc regeneration or repair with biomaterials and stem cell therapy - feasible or fiction?

机译:用生物材料和干细胞疗法进行椎间盘的再生或修复-可行还是虚构?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The "gold standard" for treatment of intervertebral disc herniations and degenerated discs is still spinal fusion, corresponding to the saying "no disc - no pain". Mechanical prostheses, which are currently implanted, do only have medium outcome success and have relatively high re-operation rates. Here, we discuss some of the biological intervertebral disc replacement approaches, which can be subdivided into at least two classes in accordance to the two different tissue types, the nucleus pulposus (NP) and the annulus fibrosus (AF). On the side of NP replacement hydrogels have been extensively tested in vitro and in vivo. However, these gels are usually a trade-off between cell biocompatibility and load-bearing capacity, hydrogels which fulfill both are still lacking. On the side of AF repair much less is known and the question of the anchoring of implants is still to be addressed. New hope for cell therapy comes from developmental biology investigations on the existence of intervertebral disc progenitor cells, which would be an ideal cell source for cell therapy. Also notochordal cells (remnants of the embryonic notochord) have been recently pushed back into focus since these cells have regenerative potential and can activate disc cells. Growth factor treatment and molecular therapies could be less problematic. The biological solutions for NP and AF replacement are still more fiction than fact. However, tissue engineering just scratched the tip of the iceberg, more satisfying solutions are yet to be added to the biomedical pipeline.
机译:治疗椎间盘突出症和变性椎间盘的“金标准”仍然是脊柱融合术,相当于“无椎间盘-无疼痛”的说法。目前植入的机械假体仅取得了中等程度的成功,并且具有较高的再手术率。在这里,我们讨论一些生物椎间盘置换方法,根据两种不同的组织类型,即髓核(NP)和纤维环(AF),可以将其细分为至少两类。在NP替代方面,水凝胶已经在体外和体内进行了广泛的测试。然而,这些凝胶通常是细胞生物相容性和承载能力之间的折衷,同时仍缺乏实现两者的水凝胶。在AF修复方面,人们所知甚少,并且植入物的锚固问题仍待解决。细胞治疗的新希望来自对椎间盘祖细胞存在的发育生物学研究,这将成为细胞治疗的理想细胞来源。最近,脊索细胞(胚胎脊索的残余物)也被重新聚焦,因为这些细胞具有再生潜能并可以激活椎间盘细胞。生长因子治疗和分子疗法的问题可能较少。 NP和AF替代的生物解决方案仍然是虚构的,而不是事实。但是,组织工程学只是刮开了冰山一角,还没有将更令人满意的解决方案添加到生物医学管道中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号